All In Biotech

Drug Trial Radar · NCT05702489

A Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of ZX-7101A Tablets in Adults with Uncomplicated Influenza

Last checked: Nov 20, 2026Latest source record: Nov 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

900

Actual

Start

Jul 17, 2022

Primary completion

May 26, 2023

Study completion Oct 13, 2023

Sponsor

Sponsor type
Industry
First posted
Jan 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to compare ZX-7101A in Chinese Adults patients with uncomplicated influenza. The main questions it aims to answer are: * The efficacy of ZX-7101A in Chinese Adults patients with uncomplicated influenza. * The safety of ZX-7101A in Chinese Adults patients with uncomplicated influenza.

Conditions

  • Influenza, Human

Interventions

  • ZX-7101ADrug

    a drug to treatment influenza in Chinese adults

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The time to the remission of all influenza symptoms (hours)Time frame: from accepting ZX-7101A until the 15 days after the first dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Affiliated to Fudan University

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.